Abstract
Dendritic cells (DCs) play a pivotal role in the initiation, programming and regulation of tumor-specific immune responses. However, the DC therapy for malignant melanoma has yielded only limited clinical success. The low efficacy of vaccine strategy against melanoma will be discussed. The combination therapy with novel molecular targeted therapy and vaccine therapy might be promising.[Skin Cancer (Japan) 2009 ; 24 : 153-158]